

IODOCYCLISATIONS OF ALLYL- AMIDINES AND -UREAS


Peter A. Hunt, Christopher May, and Christopher J. Moody*

*Department of Chemistry, Imperial College of Science and Technology,
London SW7 2AY.*


Summary: Iodocyclisation of allyl-amidines (1) and -ureas (4) gives imidazolines (2) and imidazolinones (5) respectively; in contrast, bromocyclisation of the amidine (1a) results in formation of the six-membered ring (3).

The continuing interest in halogen mediated cyclisations of nitrogen containing functional groups onto neighbouring carbon carbon double bonds¹⁻⁴ prompts us to report some of our own results in this area. In connection with our work on new methods of imidazole synthesis,⁵ we chose to investigate the halocyclisation of allyl-amidines and -ureas as a route to imidazolines and imidazolinones, protected versions of vicinal diamines.


Although there are isolated reports of cyclisation of allyl amidines,^{6,7} these reactions have not been investigated in detail. We now find that *N*-allyl-benzamidines and -trichloroacetamidines, easily prepared from the corresponding allylamines and benzonitrile or trichloroacetonitrile,^{8,9} cyclise readily on treatment with iodine or *N*-iodosuccinimide (NIS). Thus treatment of *N*-allylbenzamidine (1a) with NIS in tetrahydrofuran (THF) gave the 4-iodomethyl-2-phenylimidazoline (2a) in 73% yield. The imidazoline (2a) readily loses HI to form the aromatic 4-methyl-2-phenylimidazole, although in the case of the imidazoline (2b), formed (76%) by iodocyclisation of the amidine (1b), this facile elimination is blocked. The iodocyclisation of the *N*-allyl trichloroacetamidines (1c), (1d), and (1e) was best effected using iodine and pyridine in THF rather than NIS, and resulted in the formation of the corresponding 2-trichloromethylimidazolines (2c) (88%), (2d) (86%), and (2e) (65%). Surprisingly when the halocyclisation of *N*-allylbenzamidine (1a) was carried out using *N*-bromosuccinimide the product was not the 4-bromomethylimidazoline corresponding to (2a), but rather the six-membered bromotetrahydropyrimidine (3) (88%), possibly indicating a change in reaction mechanism.



(1)




(2)




(3)

a, $R^1 = \text{Ph}$, $R^2 = R^3 = \text{H}$; b, $R^1 = \text{Ph}$, $R^2 = \text{H}$, $R^3 = \text{Me}$; c, $R^1 = \text{CCl}_3$, $R^2 = R^3 = \text{H}$;
d, $R^1 = \text{CCl}_3$, $R^2 = \text{H}$, $R^3 = \text{Me}$; e, $R^1 = \text{CCl}_3$, $R^2 = \text{Me}$, $R^3 = \text{H}$.

In order to convert the allylureas (4), prepared by reaction of the corresponding allylamines with trimethylsilyl isocyanate, into the imidazolinones (5), prior silylation is necessary to prevent cyclisation occurring on oxygen.^{3,4} Thus treatment of the urea (4a) with trimethylsilyl trifluoromethanesulphonate (2 equiv) and triethylamine (2.2 equiv) in dichloromethane, followed by reaction of the crude product with iodine in THF gave the 4-iodomethylimidazolin-2-one (5a) (83%). Similarly the allylurea (4b) gave the imidazolinone (5b) (71%).



(4)



(5)

a, $R = \text{Me}$; b, $R = \text{CH}_2\text{Ph}$

We thank Drs. P. L. Myers and C. Smith for helpful discussions, and the S.E.R.C. and Glaxo Group Research (Greenford) for studentships (to C.M. and P.A.H. respectively), and the Royal Society of Chemistry for a Hickinbottom Fellowship (to C.J.M.).

References

- 1 A. Bongini, G. Cardillo, M. Orena, S. Sandri, and C. Tomasini, *J. Org. Chem.*, 1986, 51, 4905, and references therein.
- 2 M. Hiram, M. Iwashita, Y. Yamazaki, and S. Ito, *Tetrahedron Lett.*, 1984, 25, 4963.
- 3 S. Knapp, K. E. Rodrigues, A. T. Levorse, and R. M. Orna, *Tetrahedron Lett.*, 1985, 26, 1803.
- 4 S. W. McCombie and T. L. Nagabhushan, *Tetrahedron Lett.*, 1987, 28, 5395.
- 5 M. Casey, C. J. Moody, and C.W. Rees, *J. Chem. Soc., Perkin Trans. 1*, 1984, 1933; M. Casey, C. J. Moody, C.W. Rees, and R. G. Young, *ibid.*, 1985, 741.
- 6 I. I. Ershova, Yu. I. Gevaza, and V. I. Staninets, *Ukr. Khim. Zh.*, 1977, 43, 884.
- 7 J. I. Ogonor and R. J. Grout, *Niger. J. Pharm.*, 1981, 12, 445.
- 8 M. W. Partridge and A. Smith, *J. Chem. Soc., Perkin Trans. 1*, 1973, 453.
- 9 W. S. Saari, M. B. Freedman, J. R. Huff, S. W. King, A. W. Raab, S. J. Bergstrand, E. L. Engelhardt, A. Scriabine, G. Morgan, A. Morris, J. M. Stavorski, R. M. Noll, and D. E. Duggan, *J. Med. Chem.*, 1978, 21, 1283.

(Received in UK 18 April 1988)